Paul Hastings LLP advised Chardan Capital Markets and Invest Securities as joint global coordinators and bookrunners in connection with GenSight Biologics’ private placement (PIPE). GenSight Biologics (Euronext: SIGHT) is a French biopharma company focused on developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders.

Partner Max Kirchner led the cross-border Paul Hastings team, which also included Co-head of Equity Capital Markets and Co-chair of the Corporate Life Sciences Group Seo Salimi and partner Charles Cardon.

About Paul Hastings

With widely recognized elite teams in finance, mergers & acquisitions, private equity, restructuring and special situations, litigation, employment, and real estate, Paul Hastings is a premier law firm providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers, and corporations.